clinical trial · NCT07260812
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
TCRx Therapeutics Co.Ltd·phase1·recruiting·n = 18
Non-Hodgkin LymphomaDiffuse Large B Cell Lymphoma (DLBCL)KSV01 Injection
brief summary
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 Injection for patients with diffuse large B-cell lymphoma.
started
Sep 1, 2025
primary completion
Dec 31, 2028
completion
Dec 31, 2028
last updated
Apr 13, 2026
official title
A Phase I Clinical Study on the Safety, Tolerability, and Efficacy of KSV01 Injection in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol